by Kelley Tracy | Aug 15, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as the PI, Entitled “Small Molecule Antagonists of PF4 for the Treatment...
by Kelley Tracy | Jul 5, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces that the FDA has Completed its Review of FC-4157 (also known as BHV-4157) Investigational New Drug Application (IND) Filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd Doylestown, PA. July 5,...
by Kelley Tracy | Mar 21, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct-to-Phase II SBIR Grant from the National Institutes of Health Entitled “Development of Topical Antiviral Agents for Treating Molluscum Contagiosum” Doylestown, PA. March 21,...
by Kelley Tracy | Feb 10, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Selected to Participate in the Spring, 2016 I-Corps Program of the National Institutes of Health Doylestown, PA. February 10, 2016- FCCDC is pleased to announce that it has been selected to participate...
by Kelley Tracy | Oct 30, 2015 | Uncategorized
The Fox Chase Chemical Diversity Center is Mentioned in a Press Release by the University of Pennsylvania Doylestown, PA. October 30, 2015- FCCDC is pleased to announce that it has been mentioned in this press release by the University of...
